Effect of darunavir on lipid profile in HIV-infected patients

HIV Clinical Trials

Volumn 13, Issue 5, 2012, Pages 256-270

  Overton, Edgar Turner ^a   Arathoon, Eduardo ^b   Baraldi, Ezio ^c   Tomaka, Frank ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b Clinica Familiar Luis Angel Garcia   (Guatemala)

^c Trialtech Clinical Research   (South Africa)

^d Tibotec Inc   (United States)

Author keywords

darunavir; lipid; protease inhibitor

Indexed keywords

ATAZANAVIR; CHOLESTEROL; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LOW DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS; LIPIDS; SULFONAMIDES;

EID: 84868708516     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1305-256     Document Type: Review

References (90)

1. Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008;372: 293-299.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodefi ciency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338: 853-860. (Pubitemid 28135961)
3. Sax PE, Kumar P. Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr. 2004;37: 1111-1124. (Pubitemid 39166645)
4. Doser N, Sudre P, Telenti A, et al. Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. J Acquir Immune Defi c Syndr. 2001;26: 389-390. (Pubitemid 32436007)
5. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17: 1179-1193. (Pubitemid 36667761)
6. Friis-Møller N, Thiébaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil. 2010;17: 491-501.
7. Worm SW, Kamara DA, Reiss P, et al. Elevated triglycerides and risk of myocardial infarction in HIV-positive persons. AIDS. 2011; 25: 1497-1504.
8. Gallant JE, Staszewski S, Pozniak AL, et al. Effi cacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. J Am Med Assoc. 2004;292: 191-201. (Pubitemid 38917996)
9. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29: 21-31. (Pubitemid 34094303)
10. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomised trial of nucleoside nonnucleo-side and protease inhibitor sparing regimens for initial HIV treatment. AIDS. 2009;23: 1108-1118.
11. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA.2003;289: 2978-2982. (Pubitemid 37430100)
12. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodefi ciency syndrome. J Clin Endocrinol Metab. 1992;74: 1045-1052.
13. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6: 114-121. (Pubitemid 40425975)
14. Blum A, Hadas V, Burke M, Yust I, Kessler A. Viral load of the human immunodefi ciency virus could be an independent risk factor for endothelial dysfunction. Clin Cardiol. 2005;28: 149-153. (Pubitemid 40364508)
15. Baker JV, Duprez D. Biomarkers and HIV-associated cardiovascular disease. Curr Opin HIV AIDS. 2010;5: 511-516.
16. Strategies for Management of Antiretroviral Therapy (SMART) Study Group; El-Sadr WM, Lundgren JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355: 2283-2296. (Pubitemid 44837777)
17. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360: 1747-1748. (Pubitemid 35447907)
18. Silverberg MJ, Leyden W, Hurley L, et al. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med. 2009;150: 301-313.
19. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfi navir for the initial treatment of HIV infection. N Engl J Med. 2002;346: 2039-2046. (Pubitemid 34680595)
20. Carey D, Amin J, Boyd M, Petoumenos K, Emery S. Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65: 1878-1888.
21. Bánhegyi D, Katlama C, da Cunha CA, et al. Week 96 effi-cacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN. Curr HIV Res. 2012;10: 171-181.
22. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133: 21-30. (Pubitemid 30432540)
23. Tibotec. Prezista: summary of product characteristics. 2010. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000183/WC500051481.pdf. Accessed February 13, 2012.
24. Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. 2007 disease profi le. Atlanta, GA: Centers for Disease Control and Prevention; 2009: 7-14.
25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285: 2486-2497.
26. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodefi-ciency virus-associated lipodystrophy syndrome. Blood. 2000;95: 3191-3198. (Pubitemid 30321172)
27. Kotler D P, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defi c Syndr Hum Retro-virol. 1999;20: 228-237. (Pubitemid 29156959)
28. Clotet B, Negredo E. HIV protease inhibitors and dyslipid-emia. AIDS Rev. 2003;5: 19-24.
29. Stein JH. Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis. 2003;45: 293-304. (Pubitemid 36293025)
30. Carper MJ, Cade WT, Cam M, et al. HIV-protease inhibitors induce expression of suppressor of cytokine signaling-1 in insulin-sensitive tissues and promote insulin resistance and type 2 diabetes mellitus. Am J Physiol Endocrinol Metabol. 2008;294:E558-E567. (Pubitemid 351355226)
31. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19: 1375-1383. (Pubitemid 41800673)
32. Kannel WB, Giordano M. Long-term cardiovascular risk with protease inhibitors and management of the dyslipid-emia. Am J Cardiol. 2004;94: 901-906. (Pubitemid 39349553)
33. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profi les in antiret-roviral-therapy-naive patients infected with HIV-1. PLoS Med. 2004;1:E19.
34. van der Valk M, Kastelein JJ, Murphy RL, et al. Nevi-rapine containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profi le. AIDS. 2001;15: 2407-2414. (Pubitemid 34014609)
35. Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan T P. Lipid changes in patients initiating efavirenz-and indinavir-based antiretroviral regimens. HIV Clin Trials. 2003;4: 29-36. (Pubitemid 36336095)
36. Goldberg IJ. Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metabol. 2001;86: 965-971. (Pubitemid 32322966)
37. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005;165: 1179-1184. (Pubitemid 40720744)
38. Bevilacqua M, Dominguez LJ, Barbagallo M. Insulin resistance and the cardiometabolic syndrome in HIV infection. J Cardiometab Syndr. 2009;4: 40-43.
39. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112: 3066-3072. (Pubitemid 43113437)
40. DAD Study Group, Friis-Møller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356: 1723-1735. (Pubitemid 46658704)
41. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS. 2000;14: 51-57. (Pubitemid 30072077)
42. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353: 2093-2099. (Pubitemid 29278477)
43. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodefi ciency virus-infected anti-retroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008;52: 569-576.
44. Bristol-Meyers Squibb. Reyataz: summary of product characteristics. 2009. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000494/WC500056380.pdf. Accessed February 13, 2012.
45. Gatell J, Salmon-Ceron D, Lazzarin A, et al; for the SWAN Study Group. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with viro-logic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44: 1484-1492. (Pubitemid 46801594)
46. Mallolas J, Podzamczer D, Milinkovic A, et al. Effi cacy and safety of switching from boosted lopinavir to boosted ata-zanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study. J Acquir Immune Defi c Syndr. 2009;51: 29-36.
47. Squires KE, Young B, Dejesus E, et al. Similar effi cacy and tolerability of atazanavir compared with atazanavir/ritona-vir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010;24: 2019-2027.
48. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlip-idemia. J Acquir Immune Defi c Syndr. 2005;39: 174-180. (Pubitemid 40741115)
49. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdo-lescentGL.pdf. Accessed February 13, 2012.
50. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010. Recommendations of the International AIDS Society USA Panel. JAMA. 2010;304: 321-333.
51. Tomaka F, Lefebvre E, Sekar V, et al. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. HIV Med. 2009;10: 318-327.
52. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profi les? J Infect Dis. 2004;189: 1056-1074. (Pubitemid 38373099)
53. Thiebaut R, Dabis F, Malvy D, Jacqmin-Gadda H, Mercie P, Daucourt Valentin V. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). J Acquir Immune Defi c Syndr. 2000;23: 261-265.
54. Aberg JA, Tebas P, Overton ET, et al. METABOLIK (Metabolic Evaluation in Treatment-naives Assessing the impact of two BOosted protease inhibitors in LIpids and other marKers [published online ahead of print April 2, 2012]. AIDS Res Hum Retroviruses. PMID: 22352336.
55. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med. 2006;3: 144-153.
56. Ortiz R, Dejesus E, Khanlou H, et al. Effi cacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22: 1389-1397.
57. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23: 1679-1688.
58. Baraldi E, Morales-Ramírez J, Schneider S, et al. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on lipid parameters and anthropometrics in treatment-naïve, HIV-1-infected ARTEMIS patients at Week 96. In: Program and abstract of the 5th IAS Conference on HIV Pathogen-esis, Treatment and Prevention; July 19-22, 2009; Cape Town, South Africa. Abstract MOPEB034.
59. Madruga J V, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370: 49-58. (Pubitemid 47023100)
60. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18: 499-502.
61. Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients. AIDS. 2011;25: 929-939.
62. Arribas J, Arathoon E, Gonsalez CR, et al. Effects of once-daily versus twice-daily darunavir/ritonavir on lipid parameters at week 48 in treatment-experienced, HIV-1-infected patients with no darunavir resistance-associated mutations in the ODIN study. In: Program and abstracts of the XVIII International AIDS Conference; July 18-23, 2010; Vienna, Austria. Abstract WEPE0115.
63. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21: 395-402.
64. Molina JM, Cohen C, Katlama C, et al. Safety and effi cacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defi c Syndr. 2007;46: 24-31. (Pubitemid 47514614)
65. Arasteh K, Yeni P, Pozniak A, et al. Effi cacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir Ther. 2009;14: 859-864.
66. Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Int Med. 2010;153: 349-357.
67. Currier JS, Martorell C, Osiyemi O, et al. Effects of daruna-vir/ritonavir-based therapy on metabolic and anthropomet-ric parameters in women and men over 48 weeks. AIDS Patient Care STDS. 2011;25: 333-340.
68. Hill A, Sawyer W, Gazzard B. Effects of fi rst-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials. 2009;10: 1-12.
69. Wilkin A, Pozniak AL, Morales-Ramirez J, et al. Long-term effi cacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses. 2012;28: 437-446.
70. Cohen CJ, Molina JM, Cassetti I, et al. Pooled week 96 effi cacy, resistance and safety results from the doubleblind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-1-infected adults. In: Program and abstracts of the 6th International AIDS Society Conference on HIV Pathogen-esis, Treatment and Prevention; July 17-20, 2011; Rome, Italy. Abstract TULBPE032.
71. Fätkenheuer G, Duvivier C, Rieger A, et al. Lipid profi les for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. J Antimicrob Chemother. 2012;67: 685-690.
72. Gotuzzo E, Markowitz M, Ratanasuwan W, et al. Sustained effi cacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: fi nal results of a randomized, controlled, Phase II study (protocol 004) [published online ahead of print 2012]. J Acquir Immune Defi c Syndr.
73. Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with teno-fovir/emtricitabine for treatment-naive human immunode-fi ciency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis. 2011;53: 807-816.
74. MacInnes A, Lazzarin A, Di Perri G, et al. Maraviroc can improve lipid profi les in dyslipidemic patients with HIV: results from the MERIT trial. HIV Clin Trials. 2011;12: 24-36.
75. Nguyen A, Calmy A, Delhumeau C, et al. A randomized crossover study to compare efavirenz and etravirine treatment. AIDS. 2011;25: 57-63.
76. Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS. 2011;25: 1481-1487.
77. Martínez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS. 2010;24: 1697-1707.
78. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritona-vir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multi-centre, double-blind, randomised controlled trials. Lancet. 2010;375: 396-407.
79. Mills A, Cohen C, DeJesus E, et al. Virologic suppression is maintained in virologically suppressed HIV-1 infected subjects switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single-tablet regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR: week 24 results of study 264-111. In: Program and abstracts of the 18th Annual Conference of the British HIV Association; April 18-20, 2012; Birmingham, UK. Abstract P186.
80. Palella F, Tebas P, Gazzard B, et al. SPIRIT study: switching to emtricitabine/rilpivirine/tenofovir df (FTC/RPV/TDF) single-tablet regimen (STR) from a ritonavir-boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors (NRTIS) maintains HIV suppression and improves serum lipids in HIV-1 infected subjects. In: Program and abstracts of the XIX International AIDS Conference; July 22-27, 2012; Washington DC, USA. Abstract TUAB0104.
81. Waters L, Fisher M, Winston A, et al.A phase IV, doubleblind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. AIDS. 2011;25: 65-71.
82. Francisci D, Giannini S, Baldelli F, et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction. AIDS. 2009;23: 589-596.
83. Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS. 2010;24: 1509-1517.
84. Blake GJ, Ridker PM. C-reactive protein and other infl am-matory risk markers in acute coronary syndromes. J Am Coll Cardiol. 2003;41: 37S-42S. (Pubitemid 36223345)
85. Phillips AN, Carr A, Neuhaus J, et al. Interruption of anti-retroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13: 177-187. (Pubitemid 351535369)
86. Duprez DA, Kuller LH, Tracy R, et al. INSIGHT SMART Study Group. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis. 2009;207: 524-529.
87. Neuhaus J, Jacobs DR Jr, Baker J V, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201: 1788-1795.
88. Kalayjian RC, Machekano RN, Rizk N, et al. Pretreat-ment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010;201: 1796-1805.
89. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8: 373-418.
90. Visnegarwala F, Maldonado M, Sajja P, et al. Lipid lowering effects of statins and fi brates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect. 2004;49: 283-290. (Pubitemid 39341773)